| Paula M Gardiner, MD | |
|
55 Lake Ave N, Worcester, MA 01655-0002 | |
| (508) 334-2818 | |
| (774) 441-7799 |
| Full Name | Paula M Gardiner |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 24 Years |
| Location | 55 Lake Ave N, Worcester, Massachusetts |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1114964731 | NPI | - | NPPES |
| 110036702A | Medicaid | MA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 216578 (Massachusetts) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Cambridge Health Alliance | Cambridge, MA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Cambridge Public Health Commission | 8921910894 | 536 |
News Archive
Emerging Healthcare Solutions, Inc. announced today that the Company has signed an option with Regenevita, owner of the right to license Neo Natal Progenitor Cell Expansion Technology in Latin America. The core technology on which the Regenevita technology is based was originally developed by NASA, the National Aeronautics and Space Administration, and was sub-licensed to Regenevita for use with Neo Natal Progenitor Cell Expansion.
The January issue of European Urology, the official journal of the European Association of Urology published by Elsevier, will feature new recommendations on late-onset hypogonadism (LOH), recently formulated by major scientific organizations.
The MEDICREA Group, listed on Alternext by NYSE - Euronext Paris, a company specialized in the development of innovative surgical technologies for the treatment of spinal pathologies, announces its audited 2011 annual results approved by the Board meeting of March 29th 2012, as well as its sales for the 1st quarter of 2012.
Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the first over-the-counter (OTC) fully at-home diagnostic test for COVID-19.
Studies suggest that neurotrophic factors, which play a role in the development and survival of neurons, have significant therapeutic and restorative potential for neurologic diseases such as Huntington's disease. However, clinical applications are limited because these proteins cannot easily cross the blood brain barrier, have a short half-life, and cause serious side effects.
› Verified 7 days ago
| Entity Name | Umass Memorial Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1760445373 PECOS PAC ID: 4284539891 Enrollment ID: O20040113000267 |
News Archive
Emerging Healthcare Solutions, Inc. announced today that the Company has signed an option with Regenevita, owner of the right to license Neo Natal Progenitor Cell Expansion Technology in Latin America. The core technology on which the Regenevita technology is based was originally developed by NASA, the National Aeronautics and Space Administration, and was sub-licensed to Regenevita for use with Neo Natal Progenitor Cell Expansion.
The January issue of European Urology, the official journal of the European Association of Urology published by Elsevier, will feature new recommendations on late-onset hypogonadism (LOH), recently formulated by major scientific organizations.
The MEDICREA Group, listed on Alternext by NYSE - Euronext Paris, a company specialized in the development of innovative surgical technologies for the treatment of spinal pathologies, announces its audited 2011 annual results approved by the Board meeting of March 29th 2012, as well as its sales for the 1st quarter of 2012.
Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the first over-the-counter (OTC) fully at-home diagnostic test for COVID-19.
Studies suggest that neurotrophic factors, which play a role in the development and survival of neurons, have significant therapeutic and restorative potential for neurologic diseases such as Huntington's disease. However, clinical applications are limited because these proteins cannot easily cross the blood brain barrier, have a short half-life, and cause serious side effects.
› Verified 7 days ago
| Entity Name | Cambridge Public Health Commission |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1932313228 PECOS PAC ID: 8921910894 Enrollment ID: O20050808000725 |
News Archive
Emerging Healthcare Solutions, Inc. announced today that the Company has signed an option with Regenevita, owner of the right to license Neo Natal Progenitor Cell Expansion Technology in Latin America. The core technology on which the Regenevita technology is based was originally developed by NASA, the National Aeronautics and Space Administration, and was sub-licensed to Regenevita for use with Neo Natal Progenitor Cell Expansion.
The January issue of European Urology, the official journal of the European Association of Urology published by Elsevier, will feature new recommendations on late-onset hypogonadism (LOH), recently formulated by major scientific organizations.
The MEDICREA Group, listed on Alternext by NYSE - Euronext Paris, a company specialized in the development of innovative surgical technologies for the treatment of spinal pathologies, announces its audited 2011 annual results approved by the Board meeting of March 29th 2012, as well as its sales for the 1st quarter of 2012.
Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the first over-the-counter (OTC) fully at-home diagnostic test for COVID-19.
Studies suggest that neurotrophic factors, which play a role in the development and survival of neurons, have significant therapeutic and restorative potential for neurologic diseases such as Huntington's disease. However, clinical applications are limited because these proteins cannot easily cross the blood brain barrier, have a short half-life, and cause serious side effects.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Paula M Gardiner, MD Po Box 415348, Boston, MA 02241-5348 Ph: (800) 225-8885 | Paula M Gardiner, MD 55 Lake Ave N, Worcester, MA 01655-0002 Ph: (508) 334-2818 |
News Archive
Emerging Healthcare Solutions, Inc. announced today that the Company has signed an option with Regenevita, owner of the right to license Neo Natal Progenitor Cell Expansion Technology in Latin America. The core technology on which the Regenevita technology is based was originally developed by NASA, the National Aeronautics and Space Administration, and was sub-licensed to Regenevita for use with Neo Natal Progenitor Cell Expansion.
The January issue of European Urology, the official journal of the European Association of Urology published by Elsevier, will feature new recommendations on late-onset hypogonadism (LOH), recently formulated by major scientific organizations.
The MEDICREA Group, listed on Alternext by NYSE - Euronext Paris, a company specialized in the development of innovative surgical technologies for the treatment of spinal pathologies, announces its audited 2011 annual results approved by the Board meeting of March 29th 2012, as well as its sales for the 1st quarter of 2012.
Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the first over-the-counter (OTC) fully at-home diagnostic test for COVID-19.
Studies suggest that neurotrophic factors, which play a role in the development and survival of neurons, have significant therapeutic and restorative potential for neurologic diseases such as Huntington's disease. However, clinical applications are limited because these proteins cannot easily cross the blood brain barrier, have a short half-life, and cause serious side effects.
› Verified 7 days ago
Dr. Pankaj Anil Ksheersagar, M.B.B.S.,M.D Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 119 Belmont St, Worcester, MA 01605 Phone: 508-334-5571 | |
Parveen Gill, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 281 Lincoln St, Med Staff Svcs, Worcester, MA 01605 Phone: 508-334-8015 | |
Rajiv Balasuriya, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 281 Lincoln St, Medical Staff Svcs, Worcester, MA 01605 Phone: 508-334-8015 | |
Lori Dilorenzo, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 10 Mechanic St, Attn: Damaris Diaz, Worcester, MA 01608 Phone: 508-792-5400 Fax: 508-831-0074 | |
Patricia L. Seymour, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 119 Belmont St, Hospital Medicine, Worcester, MA 01605 Phone: 503-334-5571 | |
Dr. Lee A Mancini, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 281 Lincoln St, Worcester, MA 01605 Phone: 508-334-5812 | |
Mrs. Isabella Anna Richard, FNP Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 926 Southbridge St Apt 17, Worcester, MA 01610 Phone: 508-353-4611 |